Interest in metabolic interventions for psychiatric disorders has grown rapidly over the past decade. Among these, the ketogenic diet (KD)—a high-fat, very low-carbohydrate dietary approach—has generated particular enthusiasm, driven by preclinical data and case reports suggesting potential antidepressant effects. Until now, however, high-quality randomized evidence in treatment-resistant depression (TRD) has been limited.
A newly published randomized clinical trial in JAMA Psychiatry provides the most rigorous test to date of whether a ketogenic diet offers meaningful antidepressant benefits in adults with TRD—and just as importantly, clarifies its limitations.
Why This Study Matters
Patients with TRD often seek nonpharmacologic and lifestyle-based interventions, especially after multiple medication failures. Diet-based approaches are appealing because they are perceived as “natural” and potentially disease-modifying. However, depression trials are especially vulnerable to placebo effects, expectancy, and nonspecific support, making controlled designs essential.
This study directly addresses those concerns by comparing a ketogenic diet not to usual care, but to a well-matched active-control diet with equivalent professional support and attention.
Study Overview
Both groups received substantial clinical contact, thereby minimizing the risk that improvements could be attributed to increased attention or care.
Key Findings
Depression severity decreased markedly in both the ketogenic and control diet groups. This highlights the decisive role of structured support, engagement, and expectancy in TRD trials.
At 6 weeks, the ketogenic diet was associated with a statistically significant but modest additional reduction in PHQ-9 scores compared with the control diet (difference ≈ −2.2 points). By 12 weeks, this between-group difference was no longer statistically significant.
Significantly, the observed effect size fell below the prespecified threshold for a minimal clinically significant difference, raising questions about the real-world clinical impact.
There were no consistent differences between groups in anxiety, anhedonia, cognition, quality of life, or functional outcomes. A transient improvement in anxiety was observed at 12 weeks, but it was not robust across time points.
While adherence during the supported phase was relatively high, most participants discontinued the ketogenic diet once intensive support ended. Only a small minority continued the diet regularly at follow-up, underscoring feasibility challenges in routine clinical practice.
Clinical Implications
This trial offers a nuanced and clinically responsible message:
For clinicians treating TRD, these findings suggest that ketogenic diets should not be viewed as a stand-alone or primary intervention, but rather as an adjunctive, experimental approach that may be appropriate for carefully selected, highly motivated patients within a structured program.
Looking Ahead
Future research will need to determine whether:
As the field of interventional psychiatry evolves, this study represents a significant step forward—moving dietary interventions from anecdote toward evidence, while maintaining appropriate clinical caution.
Reference
Gao M, Kirk M, Knight H, et al. A ketogenic diet for treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. Published online February 4, 2026. doi:10.1001/jamapsychiatry.2025.4431
Contact
Disclaimer
This article was created with the assistance of artificial intelligence (AI) to support clarity and readability. All medical and scientific content has been reviewed and approved by Joao L. de Quevedo, MD, PhD, Director of the UTHealth Houston Center for Interventional Psychiatry. This content is for educational purposes only and does not replace professional medical advice.